Results 21 to 30 of about 3,310,810 (118)

Targeting in Cancer Therapies [PDF]

Medical Sciences, 2016
Drug developers recruit and combine principles, procedures and strategies from chemistry, pharmacology, nanotechnology and biotechnology, focusing on the generation of functional vehicles as nano-carriers of drugs for improved stability and enhanced intracellular delivery.[...]
Ramon Mangues, Esther Vázquez, Antonio Villaverde   +2 more
openaire   +4 more sources

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

OncoImmunology, 2023
Despite breakthroughs in immune checkpoint inhibitors (ICI), the majority of tumors, including those poorly infiltrated by CD8+ T cells or heavily infiltrated by immunosuppressive immune effector cells, are unlikely to result in clinically meaningful ...
Debayan Mukherjee, Erminia Romano, Richard Walshaw, Leo A. H. Zeef, Antonia Banyard, Stephen J. Kitcatt, Eleanor J. Cheadle, Karoliina Tuomela, Swati Pendharkar, Aws Al-Deka, Beatrice Salerno, Sophie Raby, Ian G. Mills, Jamie Honeychurch, Tim M. Illidge   +14 more
doaj   +1 more source

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors

Molecular Therapy: Oncolytics, 2021
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells.
Nicola E. Annels, Guy R. Simpson, Mick Denyer, Mehreen Arif, Matt Coffey, Alan Melcher, Kevin Harrington, Richard Vile, Hardev Pandha   +8 more
doaj   +1 more source

Bone-Targeted Therapy [PDF]

Geburtshilfe und Frauenheilkunde, 2015
Bisphosphonates and denosumab are well established components of the therapy for osteoporosis and osseous metastases. Their relevance in the adjuvant situation for breast cancer patients is being discussed in part controversially due to the heterogeneous nature of the available data.
J, Salmen, M, Banys-Paluchowski, T, Fehm
openaire   +2 more sources

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

Nature Communications
The combination of radiotherapy/chemoradiotherapy and immune checkpoint blockade can result in poor outcomes in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
Emmanuel C. Patin, Pablo Nenclares, Charleen Chan Wah Hak, Magnus T. Dillon, Anton Patrikeev, Martin McLaughlin, Lorna Grove, Shane Foo, Heba Soliman, Joao P. Barata, Joanna Marsden, Holly Baldock, Jim Gkantalis, Victoria Roulstone, Joan Kyula, Amy Burley, Lisa Hubbard, Malin Pedersen, Simon A. Smith, Eleanor Clancy-Thompson, Alan A. Melcher, Masahiro Ono, Antonio Rullan, Kevin J. Harrington   +23 more
doaj   +1 more source

Targeted Radionuclide Therapy [PDF]

Cancers, 2011
Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the
Ersahin, Devrim, Doddamane, Indukala, Cheng, David   +2 more
openaire   +2 more sources

What role does pyroptosis play in cancer?

Molecular Metabolism, 2022
Background: Pyroptosis has been attracting much attention recently. We have briefly compared its differences and similarities with other programmed deaths and the process of its study. With further exploration of the caspase family, including caspase-1/3/
Chen Huang, Jian Li, Chenliang Zhang
doaj   +1 more source

Histone variant H2A.J is an epigenetic regulator of metastasis in lung adenocarcinoma

Cell Death and Disease
Metastasis is a major contributor to poor patient survival in lung adenocarcinoma (LUAD); however, the underlying mechanisms remain incompletely understood.
Dong-Gun Kim, Eun-Young Choi, Hye-Mi Ahn, Kyungho Kim, Youn-Jae Kim   +4 more
doaj   +1 more source

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Molecular Cancer, 2021
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi   +4 more
doaj   +1 more source

Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy

Frontiers in Oncology, 2022
Cholesterol metabolism is often dysregulated in cancer. Squalene monooxygenase (SQLE) is the second rate-limiting enzyme involved in cholesterol synthesis.
Yuheng Zou, Hongying Zhang, Feng Bi, Qiulin Tang, Huanji Xu   +4 more
doaj   +1 more source